The impact of short chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon by Christiansen, Charlotte Bayer et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The impact of short chain fatty acids on GLP-1 and PYY secretion from the isolated
perfused rat colon
Christiansen, Charlotte Bayer; Gabe, Maria Buur Nordskov; Svendsen, Berit; Dragsted, Lars
Ove; Rosenkilde, Mette; Holst, Jens Juul
Published in:
American Journal of Physiology: Gastrointestinal and Liver Physiology
DOI:
10.1152/ajpgi.00346.2017
Publication date:
2018
Document version
Peer reviewed version
Document license:
Unspecified
Citation for published version (APA):
Christiansen, C. B., Gabe, M. B. N., Svendsen, B., Dragsted, L. O., Rosenkilde, M., & Holst, J. J. (2018). The
impact of short chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. American
Journal of Physiology: Gastrointestinal and Liver Physiology, 315(1), G53-G65.
https://doi.org/10.1152/ajpgi.00346.2017
Download date: 03. Feb. 2020
1 
 
The impact of short chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon 1 
 2 
Charlotte Bayer Christiansen1,2, Maria Buur Nordskov Gabe2, Berit Svendsen1,2, Lars Ove Dragsted3, Mette 3 
Marie Rosenkilde2, Jens Juul Holst1,2* 4 
 5 
1Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark  6 
2Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 7 
Denmark  8 
3Department of Nutrition, Exercise and Sports, University of Copenhagen, Denmark 9 
 10 
 11 
*Corresponding author: Jens Juul Holst, jjholst@sund.ku.dk  12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
2 
 
Abstract 34 
The colonic epithelium harbors a large number of endocrine cells, but little is known about the endocrine 35 
functions of the colon. However, the high density of GLP-1 and PYY secreting L-cells is of great interest 36 
because of the potential anti-diabetic and anti-obesity effects of GLP-1 and PYY. Short chain fatty acids 37 
(SCFAs) produced by local bacterial fermentation are suggested to activate the colonic free fatty acid 38 
receptors FFAR2 (GPR43) and FFAR3 (GPR41), stimulating the colonic L-cells. We used the isolated perfused 39 
rat colon as a model of colonic endocrine secretion and studied the effects of the predominant SCFAs 40 
formed: acetate, propionate and butyrate. We show that luminal and especially vascular infusion of acetate 41 
and butyrate significantly increases colonic GLP-1 secretion, and to a minor extent also PYY secretion, but 42 
only after enhancement of intracellular cAMP. Propionate neither affected GLP-1 nor PYY secretion 43 
whether administered luminally or vascularly. A FFAR2 and FFAR3 specific agonist (CFMB/AR420626) had 44 
no effect on colonic GLP-1 output, and a FFAR3 antagonist (AR399519) did not decrease the SCFA-induced 45 
GLP-1 response. However, the voltage-gated Ca2+-channel blocker nifedipine, the KATP-channel opener 46 
diazoxide and the ATP synthesis inhibitor 2,4-dinitrophenol completely abolished the responses. FFAR2 47 
receptor studies confirmed low-potent partial agonism of acetate, propionate and butyrate, compared to 48 
CFMB which is a full agonist with around 750-fold higher potency than the SCFAs. In conclusion, SCFAs may 49 
increase colonic GLP-1/PYY secretion, but FFAR2/FFAR3 do not seem to be involved. Rather, SCFAs are 50 
metabolized and appear to function as a colonocyte energy source.  51 
 52 
New & Noteworthy 53 
By the use of in situ isolated perfused rat colon we show that SCFAs primarily are used as a colonocyte 54 
energy source in the rat, subsequently triggering GLP-1 secretion independent of FFAR2 and FFAR3. 55 
Opposite many previous studies on SCFAs, FFAR2/FFAR3 and GLP-1 secretion, this experimental model 56 
allows investigation of the physiological interactions between luminal nutrients and secretion from cells 57 
whose function depend critically on their blood supply as well as nerve and paracrine interactions.   58 
 59 
 60 
 61 
 62 
 63 
 64 
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Introduction 65 
The colon serves to store and transport indigestible material, to absorb water and salt from the ileal chyme, 66 
and is also home for fermentation processes converting undigested and malabsorbed substances into 67 
absorbable moieties such as short chain fatty acids (SCFAs) (4, 28). However, the colonic mucosa also 68 
harbors a large number of enteroendocrine cells, the density of which increases towards the distal part of 69 
the gut (20, 23, 63). Very little is known about the endocrine secretion from the colon and about its 70 
endocrine functions in general, but the high abundance of the glucagon like peptide-1 (GLP-1) and peptide-71 
YY (PYY) secreting L-cells has attracted considerable interest because of the potential anti-diabetic and anti-72 
obesity effects of GLP-1 and PYY (30). In fact, analogs of GLP-1 are now widely used in the treatment of 73 
type 2 diabetes (T2D) (1, 19).  74 
In 1995 Deacon et al. demonstrated that the human colon produces biologically active GLP-1 (7-36NH2) in 75 
amounts that are large enough to have physiological importance (17). However, the best characterized 76 
stimulants for GLP-1 secretion in vivo are nutrients including glucose, amino acids and long chain fatty 77 
acids, which are absorbed in the proximal small intestine and do not reach the distal colonic L-cells (22, 38, 78 
53, 60). Accordingly, colectomized individuals have normal GLP-1 meal responses (51). Interestingly, 79 
however, L-cell secretion has been found to be increased in individuals with short-bowel syndrome but 80 
preserved colon (31). The latter suggests that the colonic cells are able to produce a significant amount of 81 
proglucagon-derived peptides, including GLP-1, which may reach the general circulation. The potential 82 
importance of this may be illustrated by patients undergoing gastric bypass surgery, who exhibit markedly 83 
increased postprandial secretion of GLP-1 and PYY, which seems to be involved in the diabetes remission 84 
and at least part of the weight loss resulting from the operation (29). Stimulation of the endogenous 85 
secretion of these hormones may therefore have important therapeutic potential, but to accomplish this 86 
goal, a better understanding of the mechanisms that regulate their secretion from the colon is necessary.  87 
 88 
Recently, changes in the gut microbiota have been linked to a variety of disorders such as T2D and obesity. 89 
It is not clear exactly how the microbiota influences host metabolism, but a proposed mechanism involves 90 
the generation of SCFAs (11, 28). The amount of SCFAs ingested with foods is minor, but a considerable 91 
production of SCFAs takes place in the distal gut as a result of bacterial fermentation of non-absorbed 92 
carbohydrate, often in the form of dietary fibers that resist digestion and absorption in the small intestine 93 
(15, 16). The primary SCFAs (>95%) generated from intestinal fermentation are acetate (C2), propionate 94 
(C3), and butyrate (C4), some of which may be absorbed and delivered to the systemic circulation (15, 32, 95 
42). Circulating plasma levels of SCFAs are in the lower micromolar range, whereas luminal concentrations 96 
of SCFAs in the colon may reach 100 mM (5, 18, 57, 69). 97 
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SCFAs have been proposed as an energy source, as enhancer of intestinal growth and as signal molecules in 98 
colonic motility (12) and ion transport (33, 36). Moreover, they are hypothesized to constitute the link 99 
between the gut microbiota and distal L-cell activity, as certain cell studies have reported increased 100 
secretion of GLP-1 and/or PYY upon SCFA administration (7, 26, 41, 48, 58, 68, 70). The mechanism by 101 
which acetate, propionate and butyrate exert their actions is believed to involve GPCRs, namely FFAR2 102 
(GPR43) and FFAR3 (GPR41) (8, 40). Both FFAR2 and FFAR3 are reported to be expressed on L-cells in the 103 
colon, whereas expression in the small intestine is more debated (33, 48, 68). FFAR3 is found to signal 104 
exclusively through the Gαi-coupled pathway, which typically is linked to suppression of gut hormone 105 
secretion. FFAR2 is likewise Gαi-coupled, but may also activate Gαq-signaling (8, 59, 68), making FFAR2 a 106 
more likely candidate for stimulating L-cell secretion. Whether FFAR2 and FFAR3 reside on the basolateral 107 
or apical membranes of the L-cells and whether they primarily detect luminal or vascular SCFAs remains to 108 
be explored.    109 
 110 
The aim of the current study was to investigate the presumed positive effects of SCFAs on colonic GLP-1 111 
and PYY secretion, including an evaluation of FFAR2 and FFAR3 as possible significant targets for the 112 
treatment of metabolic disorders. In order to do so, we used the isolated perfused rat colon as a model of 113 
colonic endocrine secretion, because it maintains correct cell polarity and vascular integrity as opposed to 114 
isolated cell cultures. Also, any observed effect can solely be allocated to the colon as the confounding 115 
influence of the rest of the body, inherent in in vivo studies, is avoided by isolating the organ.  116 
 117 
Materials and Methods 118 
Animals 119 
Handling of the donor animals was performed in accordance with international accepted guidelines and 120 
with permission from the Danish Animal Experiments Inspectorate (license no. 2013-15-2934-00833). Male 121 
Wistar rats (Janvier, Saint Berthevin Cedex, France) fed ad libitum and weighing between 250-300 g were 122 
used as donors. Animals were housed two per cage under a 12:12 hour light-dark cycle. After 123 
approximately one week of acclimatization they were used for experiments. The rats were anaesthetized 124 
with a subcutaneous injection of Hypnorm/Midazolam (0.0158 mg fentanyl citrate + 0.5 mg fluanisone + 125 
0.25 mg midazolam / 100 g) before surgery.  126 
Isolation of the colon 127 
After lack of reflexes was established, the operation was started by a midline incision exposing the 128 
abdominal cavity. The colon was cut immediately after the cecum and again approximately 10 cm distal 129 
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from cecum (average length: 10.20±0.84 cm), so that the most distal colon and rectum were not included in 130 
the preparation. Next, all vessels supplying the small intestine, the cecum and the spleen were ligated, thus 131 
avoiding perfusion of these segments. The stomach was removed after ligating the esophagus and tying off 132 
all blood supplies. Following removal of the stomach, the renal kidney stalks were ligated, and the celiac 133 
artery partly perfusing the pancreas was ligated too. Tubing was inserted into the proximal colonic lumen 134 
to establish a route for luminal stimulation, and the colonic contents were washed out by gentle flushing 135 
with pre-warmed saline. The distal lumen was left open allowing contents to exit. Subsequently, aorta was 136 
ligated proximally to the superior mesenteric artery and immediately afterwards a metal catheter (1.0 mm 137 
diameter) was placed into the distal aorta and fixed with a ligature and vascular perfusion was started. 138 
Next, a draining metal catheter (1.3 mm diameter) was placed into the vena portae. Finally, the rat was 139 
euthanized and the colon kept artificially alive.  140 
Experimental protocol 141 
After isolation, the colon was perfused in situ at a constant vascular flow rate of 3 ml/min while saline was 142 
continuously infused into the colonic lumen (0.05 ml/min). After a 30 min equilibrium period each protocol 143 
started with a 10 min baseline period followed by addition of test substances. Vascularly administered test 144 
substances were infused for 10 min at a flow rate of 0.15 ml/min, while luminally administered stimulations 145 
were infused for 20 min. Luminal test substances were infused at an initial rate of 0.25 ml/min for the first 146 
5 min (to replace the saline solution in the lumen) and then at 0.15 ml/min throughout the rest of the 147 
stimulation period. Following luminal stimulations saline was luminally infused at 0.25 ml/min for 5 min to 148 
remove test substances. The total venous effluent was collected for 1 min periods and stored at -20ᵒC until 149 
analysis. We used equipment dedicated for rodent organ perfusion (Hugo Sachs Elektronik, March-150 
Hugstetten, Germany). The perfusion buffer was a modified Krebs-Ringer bicarbonate buffer, containing in 151 
addition 5% dextran T-70 (Pharmacosmos, Denmark, cat.no. 40014), 0.1% bovine serum albumin (Merck, 152 
cat.no. 1.12018.0500), 3.5 mM glucose and 5 mM pyruvate, fumarate and glutamate. Perfusion buffer was 153 
heated to 37ᵒC and continuously gassed throughout the experiment with 95% O2 and 5% CO2 to achieve pH 154 
7.4 and a high oxygen partial pressure. Respiration (calculated from the partial pressures of CO2 of arterial 155 
and venous perfusion buffer samples; CO2 excretion: median=17.8 µl/g, IQR=8.5-23.6 µl/g), stable perfusion 156 
pressure and vascular effluent flow rate were monitored throughout the experiments and used as an 157 
indication of the organ’s wellbeing.  158 
 159 
Test substances 160 
Bombesin (positive control, Bachem, cat.no. H-2155) was dissolved in dimethyl sulfoxide (DMSO, Sigma 161 
Aldrich, cat.no. 67-68-5) and perfusion buffer and added to give a final perfusate concentration of 10 nM. 3-162 
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Isobutyl-1-methylxanthine (IBMX, Sigma Aldrich, cat.no. I5879) was dissolved in DMSO and further diluted 163 
in perfusion buffer resulting in a final perfusate concentration of 10 µM. Stock solutions of acetate (Sigma 164 
Aldrich, cat.no. 695092), propionate (Sigma Aldrich, cat.no. 81910) and butyrate (Sigma Aldrich, cat.no. B-165 
103500) were diluted in H2O and the pH value was adjusted to 7.4 by addition of 5 M NaOH. For vascular 166 
infusions (at 1 mM) the solutions were further diluted in perfusion buffer while they were further diluted in 167 
saline when added to the lumen (100 mM). AR420626 and AR399519 (kind gifts from Thue Schwartz, NNF 168 
CBMR, Department of Biomedical Sciences, University of Copenhagen, Denmark) and CFMB ((S)-2-(4-169 
chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl)butamide, Merck Millipore, cat.no. 371725) were 170 
dissolved in DMSO and diluted in perfusion buffer to reach final concentrations of 10 µM. Nifedipine (Sigma 171 
Aldrich, cat.no N7634), diazoxide (Sigma Aldrich, cat.no D9035) and 2,4-dinitrophenol (Sigma Aldrich, 172 
cat.no D198501) were also dissolved in DMSO and diluted in perfusion buffer to final perfusate 173 
concentrations of 10-250 µM. Final concentrations of DMSO never exceeded 1% which did not influence 174 
secretion when given alone (see below). 175 
Hormone analysis  176 
GLP-1 and PYY concentrations in the venous effluent were analyzed using radioimmunoassays (RIA). GLP-1 177 
concentrations were determined using an in-house antiserum, codename 89390, which is specific for the C-178 
terminal part of amidated GLP-1 isoforms (7-36NH2 and 9-36NH2) (50). We chose to measure amidated GLP-1 179 
rather than glycine-extended GLP-1 as the amidated forms dominate in rats (37, 65). Synthetic GLP-1 7-180 
36NH2 (Bachem, cat.no H-6795.0500) was used as standard and 
125I-labeled GLP-1 7-36NH2 (a gift from Novo 181 
Nordisk A/S, Bagsværd, Denmark) as tracer. Total PYY immunoreactivity was measured with a porcine 182 
antiserum (Bachem, cat.no T-4093) using synthetic rat/porcine PYY (Bachem, cat.no H-6042) as standard 183 
and 125I-labeled porcine PYY (Perkin Elmer Life Sciences, cat.no NEX240) as tracer (65).  184 
 185 
Mass spectrometry 186 
For analysis of SCFAs we used the method of (27) with minor modifications. In brief, 40 L of the venous 187 
effluent or perfusion buffer were mixed with 10 L 200 mM 3-nitrophenylhydrazine (3-NPH) in 50% ethanol 188 
and 120 L N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) and 6% pyridine in 50% ethanol and 189 
incubated at room temperature for 30 min while shaking. This and all subsequent procedures were run in 190 
polypropylene plastic tubes or well plates in order to avoid SCFA contamination from glassware and several 191 
other plastics. The mixtures were diluted to 1 ml with 10% ethanol and 100 L internal standard (IS) was 192 
added. IS was prepared by derivatizing 50 L of a solution of 20 mM acetic acid, 10 mM propionic acid and 193 
5 mM butyric acid and 1 mg 13C6-3NPH hydrochloride in 50% ethanol with 25 L 120 mM EDC and 25 L 6% 194 
pyridine in 50% ethanol and mixing at room temperature for 30 min. A dilution series of external standards 195 
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prepared of all three SCFAs from 10-1250 M and an assay blank (50% ethanol) were all treated as 196 
described for the effluent samples. Samples, sample pools and all standards and assay blanks (all 10 L) 197 
were injected in random order into a Waters (Milford, CA) Acquity UPLC coupled through an electrospray 198 
interface to a triple quadrupole MS/MS system and concentrations determined using the vendor software 199 
(Quanlynx). The BEH C18 1.7 μm, 2.1 x 5 mm column was eluted at 40ᵒC by a gradient going from 20%-200 
100% acetonitrile with 0.01% formic acid. All MS-MS transitions, dwell times and collision energies were as 201 
described in (27). The CV% for pools (n=5) in the analytical batch was <10% and r2 for the external standard 202 
calibration curve was >0.99. 203 
 204 
Transfection and Tissue Culture 205 
COS-7 cells were cultured at 10% CO2 and 37°C in Dulbecco’s modified Eagle’s medium 1885 supplemented 206 
with 10% foetal bovine serum, 2 mM glutamine, 180 units/ml penicillin, and 45 g/ml streptomycin. 207 
Transient transfection of COS-7 cells with human and rat FFAR2 for the IP3 assays was performed using the 208 
calcium phosphate precipitation method with the addition of chloroquine (35). 209 
 210 
IP3 assay 211 
One day after transfection, COS-7 cells transiently expressing either human or rat FFAR2 (35,000 cells/well) 212 
were incubated with myo-[3H]inositol (5 μl/ml, 2 μCi/ml) in 0.1 ml of medium overnight in a 96-well plate. 213 
The following day, cells were washed twice in PBS and incubated in 0.1 ml of Hanks' balanced salt solution 214 
(Invitrogen) supplemented with 10 mM LiCl at 37°C in the presence of various concentrations of acetate, 215 
propionate, butyrate, and FFAR2 agonist (CFMB) for 90 min. Assay medium was then removed, and cells 216 
were extracted by the addition of 50 μl of 10 mM formic acid to each well, followed by incubation on ice for 217 
30–60 min. The [3H]inositol phosphates in the formic acid cell lysates were thereafter quantified by adding 218 
yttrium silicate-poly-D-Lys-coated SPA beads (66). Briefly, 35 μl of cell extract was mixed with 80 μl of SPA 219 
bead suspension in H2O (12.5 μg/μl) in a white 96-well plate. Plates were sealed and shaken on table shaker 220 
for at least 30 min. SPA beads were allowed to settle and react with the extract for at least 8 hours before 221 
radioactivity was determined using a Packard Top Count NXTTM scintillation counter (PerkinElmer Life 222 
Sciences). 223 
 224 
Statistical analysis  225 
Hormone secretion was calculated as hormone output (effluent concentration x perfusion flow). Statistical 226 
analysis of colonic hormone responses was performed by comparing mean basal outputs prior to infusion 227 
with mean outputs during infusion (5 min periods for vascular stimulations, 10 min periods for luminal 228 
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stimulations, all starting 2 min after infusion start and also stated in the figure legends). For two identical 229 
consecutive responses, statistical analysis of hormone secretion was performed by comparing the mean 230 
output during the two responses using a paired t-test (except for figure 2B and 2D and except for the 231 
comparison of vascular vs. luminal responses where an unpaired t-test was used). All statistics were 232 
performed using GraphPad Prism 6. Values of P<0.05 were considered significant and all data in the text 233 
and graphs are presented as mean±SEM. 234 
 235 
Results  236 
Acetate and butyrate, but not propionate, increase colonic GLP-1 and PYY secretion in the presence of IBMX 237 
Vascular (1mM) or luminal (100mM) stimulation with acetate, propionate or butyrate had no impact on 238 
GLP-1 or PYY output from the perfused rat colon in the absence of the phosphodiesterase inhibitor IBMX, 239 
despite greatly enhanced secretion in response to intra-arterial stimulation with 10 nM of our positive 240 
control bombesin (figure 1). Supplementing the perfusion buffer with 10 µM IBMX throughout the 241 
experiments led to a significant increase in GLP-1 responses to vascular acetate and butyrate 242 
administration and similar responses were obtained after repeated stimulation (figure 2A and E. P-values 243 
for repeated stimulation were GLP-1: acetate; p=0.278, butyrate; p=0.199, PYY: acetate; p=0.517, butyrate; 244 
p=0.443). PYY secretion was also significantly elevated upon both 1 mM acetate and butyrate 245 
administration, however, to a lesser extent than GLP-1 secretion (figure 2A and E). Luminal administration 246 
of 100 mM acetate led to a short-lasting peak in GLP-1 secretion whereas PYY secretion remained 247 
unaffected (figure 2B). Luminal infusion of 100 mM butyrate significantly increased GLP-1 and PYY secretion 248 
from the isolated perfused rat colon (figure 2F). Propionate had no impact on colonic GLP-1 or PYY 249 
secretion whether administered vascularly or luminally (figure 2C and D). In all experiments, intra-arterial 250 
administration of 10 nM bombesin was included as a positive control at the end, and did in each case result 251 
in a robust GLP-1 and PYY response (figure 2A-F).  252 
Vascular co-administration of a cocktail solution of acetate and butyrate significantly increased GLP-1 and 253 
PYY secretion from the perfused rat colon (figure 3A). Moreover, co-administration of acetate/butyrate 254 
showed a dose-dependent GLP-1 and PYY response, as colonic GLP-1 output increased 1.74-fold and colonic 255 
PYY output increased 1.60-fold when comparing responses to 0.1 mM with responses to 1 mM (figure 3A). 256 
In addition, co-administration had an additive effect on the colonic GLP-1 response compared to infusion of 257 
acetate or butyrate alone (figure 3B). PYY output was, however, not significantly changed when compared 258 
to a single SCFA infusion (figure 3B). Furthermore, colonic GLP-1 and PYY output increased upon luminal 259 
infusion of 100 mM acetate/butyrate (figure 3C). However, the response to luminal co-administration of 260 
acetate/butyrate seemed fairly similar to luminal butyrate infusion alone, in accordance with data showing 261 
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that luminal acetate alone only has minor impact on colonic hormone secretion (figure 3D). Comparing the 262 
mean output during vascular infused acetate/butyrate (1 mM) to the mean output during luminal 263 
acetate/butyrate (100 mM) infusion demonstrated that vascular stimulation resulted in a significantly 264 
higher GLP-1 response compared to the response induced by luminal stimulation (vascular: 67.6±7.3 265 
fmol/min vs. luminal: 37.0±2.9 fmol/min, p=0.0097). PYY responses to vascular and luminal 266 
acetate/butyrate administration were not significantly different (vascular: 28.9±2.9 fmol/min vs. luminal: 267 
26.7±2.5 fmol/min, p=0.755).   268 
We also measured absorption of acetate, propionate and butyrate to the vascular circulation after luminal 269 
infusion (figure 4). The concentrations reached in the venous effluent were comparable to those applied 270 
vascularly (~1 mM). However, also prestimulatory vascular acetate levels were high; this turned out to be 271 
due to presence of acetate in our perfusion buffer (perfusion buffer content: acetate; 909 µM, propionate; 272 
73 µM, butyrate; below detection limit (65 µM)).  273 
FFAR2 and FFAR3 activation have no impact on GLP-1 secretion, while a FFAR3 agonist increases PYY 274 
release from the perfused rat colon 275 
Next, we investigated the importance of the GPCRs, free fatty acid receptor-2 and -3 (FFAR2 and FFAR3), 276 
for the SCFA-induced colonic GLP-1 and PYY response. 10 µM FFAR2 specific agonist, CFMB, had no 277 
significant impact on GLP-1 and PYY output from the perfused rat colon, possibly indicating that FFAR2 is 278 
not necessarily involved in colonic hormone secretion (figure 5A). The FFAR3 specific agonist, AR420626, 279 
did not change colonic GLP-1 output, but 10 µM AR420626 significantly elevated PYY secretion (figure 5C). 280 
However, a FFAR3 specific antagonist, AR399519, did not decrease the GLP-1 or the PYY response induced 281 
by a cocktail infusion of 1 mM acetate and butyrate, suggesting that the acetate/butyrate mediated 282 
hormone response is independent of FFAR3 signaling (figure 5D). Control experiments evaluating the 283 
impact of intra-arterial DMSO administration (1% solution similar to the amount of DMSO used to dissolve 284 
test substances), revealed that DMSO alone had no impact on GLP-1 or PYY output from the perfused rat 285 
colon (GLP-1; 17.1±0.6 to 19.8±1.2 fmol/min, PYY; 15.9±1.2 to 16.8±0.6 fmol/min, n=2, data not shown). 286 
The FFAR3 specific agonist and antagonist have previously been shown to selectively activate and inhibit 287 
the Gαi-coupling of FFAR3 (21). FFAR2 couples to Gαi as well as to Gαq, and to our knowledge the FFAR2 288 
specific agonist CFMB and the SCFAs have not been tested in terms of their abilities to induce FFAR2-289 
mediated Gαq activity. An IP3 assay was therefore conducted on transiently transfected COS-7 cells 290 
expressing either human or rat FFAR2. Data showed low-potent, weak partial agonism of acetate, 291 
propionate, and butyrate on both human and rat FFAR2. For the human FFAR2 the EC50 and Emax values 292 
were 0.5 mM and 64%, 0.3 mM and 69%, and 0.5 mM and 42% for acetate, propionate and butyrate, 293 
respectively, compared to CFMB (figure 5B and table 1). For rat FFAR2 the EC50 value was 0.17 mM for all 294 
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three SCFAs, however, their Emax values ranged from 81%, 93% and 57% for acetate, propionate and 295 
butyrate, respectively, compared to CFMB (figure 5B and table 1). CFMB on the other hand appeared to be 296 
a stronger agonist both on human and rat FFAR2 with an approximately 350-600-fold better potency than 297 
the SCFAs on the human FFAR2 and a 750-fold better potency than the SCFAs on the rat FFAR2 (EC50 of 0.8 298 
and 0.2 µM on human and rat FFAR2, respectively) (figure 5B and table 1). This is consistent with the 299 
potency of CFMB identified in Gαi-mediated FFAR2 activity (21), demonstrating that lack of colonic 300 
hormone response to CFMB was not due to lack of activation of FFAR2 if present.  301 
SCFAs stimulate colonic GLP-1 and PYY secretion trough depolarization and Ca2+-influx  302 
Finally, we investigated the role of the voltage-gated Ca2+-channel blocker nifedipine, the KATP-channel 303 
opener diazoxide and the ATP synthesis inhibitor 2,4-dinitrophenol for the SCFA-induced colonic GLP-1 and 304 
PYY response. Blockage of voltage-gated Ca2+-channels (by 10 µM nifedipine) significantly reduced the GLP-305 
1 and PYY responses, suggesting that Ca2+-influx resulting from depolarization is involved in the SCFA-306 
mediated hormone secretion (figure 6A and B). The importance of depolarization was validated by 307 
administration of 250 µM diazoxide, which completely abolished the SCFA-induced GLP-1 and PYY response 308 
as well as basal hormone secretion (figure 6C and D). Furthermore, inhibiting intracellular ATP synthesis by 309 
10 µM 2,4-dinitrophenol also prevented acetate/butyrate mediated GLP-1 and PYY secretion (figure 6E and 310 
F) while responses to bombesin were unaffected  by preceding 2,4-dinitriphenol.  311 
 312 
Discussion 313 
Following the therapeutic success of incretin-based anti-diabetic drugs, research has focused on the L-cell 314 
asking whether it would be possible and beneficial to stimulate the endogenous release of GLP-1 in vivo. 315 
Moreover, the dramatic increases in GLP-1 and PYY secretion seen after bariatric surgery seem to arise 316 
from distal sources, potentially involving colonic L-cells (29, 43). Understanding the mechanisms underlying 317 
GLP-1 release is essential for further progress. In vivo, L-cells are integrated within the epithelial cell layer 318 
and are therefore differentially exposed to luminal and plasma constituents at their apical and basolateral 319 
membrane surfaces (9). This environment almost certainly impacts L-cell function, but is impossible to 320 
reestablish in single cell studies. However, in the present study we made use of a robust procedure for 321 
isolation and perfusion of the rat colon, allowing physiologically relevant studies of the dynamics of colonic 322 
endocrine secretion. In combination with single cells, where direct effects on the L-cell can be 323 
demonstrated the full picture may then be assembled. As already alluded to, it is unclear to what extent 324 
the colon contributes to postprandial circulating GLP-1 and which stimuli are the most appropriate for 325 
colonic secretion. Also, the mechanisms underlying colonic GLP-1 and PYY release are incompletely 326 
understood. In the small intestine, GLP-1/PYY secretion depends on absorption and/or signaling properties 327 
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of digested nutrients (22, 38). However, since only limited amounts of digestible nutrients normally reach 328 
the colon, other stimuli for GLP-1 secretion, like SCFAs, might be involved.  329 
First of all, our study demonstrated that the introduction of SCFAs had no effect on secretion from the rat 330 
colon unless the tissue was primed with a phosphodiesterase inhibitor (IBMX). This suggests that the SCFA 331 
signal is weak and needs interaction and probably potentiation with a cyclic nucleotide mechanism, most 332 
likely involving cAMP formation, which is known from studies of single colonic L-cells to provide a powerful 333 
stimulus to GLP-1 secretion (60, 68). Interestingly, unlike acetate and butyrate, propionate was without 334 
effect, comparable with previous work on perfused rat colon (55, 56). Secondly, our study demonstrated 335 
that vascular acetate and butyrate were stronger stimuli for GLP-1 secretion than luminal stimulation. 336 
Normally, circulating plasma levels of SCFAs are found in the lower micromolar range (acetate may reach 337 
200 µM) (18, 57, 69), so the vascularly applied concentrations used in this study may be considered rather 338 
high. However, local concentrations of SCFA at the basolateral L-cell membrane in the colon may be 339 
significantly higher than circulating levels, considering that the absorbed SCFAs must reach a high 340 
concentration in the interstitial space before they enter and mix into the total vascular outflow from the 341 
gut. Among SCFAs, acetate is the one that reaches the highest concentrations both luminally and vascularly 342 
(44, 69), while butyrate appears to be the SCFA with lowest concentration in the general circulation, 343 
perhaps because butyrate is a preferred metabolic substrate of the colonocytes (5, 39, 57, 61). The lack of 344 
impact by both vascularly and luminally administered propionate was rather surprising, since we had no 345 
prior evidence to suggest that propionate would act differently from acetate and butyrate. Here we show 346 
that acetate, propionate and butyrate all cross the epithelial cell layer in the colon as indicated by the clear 347 
and relevant increases in vascular SCFA concentration upon luminal SCFA administration. Undissociated 348 
SCFAs may be absorbed by passive diffusion, while dissociated SCFAs (the primary form in the colonic 349 
lumen and in the present experiments) are absorbed by transporters present in the apical membrane (18). 350 
Acetate measurements revealed that our perfusion buffer, and therefore also baseline samples, contained 351 
a rather high amount of acetate, which appears to be a common problem derived from the numerous 352 
contacts with various glass utensils that are used in modern laboratories. This means that the basal colonic 353 
GLP-1 and PYY secretion is under a constant influence of acetate stimulation in our model, and that 354 
vascular acetate administration (1 mM) actually results in an increase in effluent acetate concentration 355 
from around 1 mM to 2 mM instead of 0 to 1 mM. Nevertheless, the applied dose did lead to an increased 356 
GLP-1 and PYY response, demonstrating that acetate is capable of influencing colonic endocrine secretion, 357 
but indicating that the acetate mediated hormone response observed from the perfused rat colon may 358 
have been greater if no acetate was already present.   359 
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The linking of GLP-1 release to FFAR3 stimulation has raised some interesting physiological questions as 360 
FFAR3 is found to signal exclusively through the Gαi-pathway (8), which traditionally is linked to suppressed 361 
secretion (59). FFAR2 is likewise Gαi-coupled, but also couples to Gαq-signaling, activating phospholipase C 362 
and thereby triggering IP3 mediated Ca
2+ release and secretion of peptide hormones. Therefore, FFAR2 363 
activation is suggested to dominate over any FFAR3 signaling induced by SCFAs with regards to increased 364 
hormone release (6, 8, 68). Nevertheless, we observed increased secretion of PYY when the rat colon was 365 
vascularly stimulated with the FFAR3 specific agonist, AR420626, supporting that FFAR3 is expressed in the 366 
murine colon (48, 68), but only adding to the confusion regarding the stimulation mechanism. GLP-1 367 
secretion, however, was not affected by AR420626 suggesting that different signaling pathways may be 368 
responsible for colonic GLP-1 and PYY secretion and/or that the peptides are not co-secreted but arise from 369 
different L-cells with different expression profiles as also suggested previously for small intestinal L-cells 370 
(65).  Moreover, Nøhr et al. showed enhanced GLP-1 secretion (PYY not measured) from murine colonic 371 
crypt cultures in response to the same selective FFAR2 (Gαi/Gαq) and FFAR3 (Gαi) agonists applied in our 372 
study (48). Similarly, Park et al. found increased GLP-1 secretion from human NCH-H716 cells in response to 373 
a selective inverse agonist for FFAR2 (BTI-A-404), while 10 mM propionate had no effect (52). A third FFAR2 374 
ligand, AZ1729, was without effect on GLP-1 secretion from mouse colonic crypts, though it was found to 375 
be a potent activator of FFAR2 Gαi-signaling (6). In the isolated perfused rat colon, however, the FFAR2 376 
selective agonist and the FFAR3 selective antagonist had no impact on colonic hormone output. This was 377 
observed despite the FFAR3 antagonist, AR399519, previously has been demonstrated to selectively inhibit 378 
FFAR3 in stably transfected HEK293 cells (21). We tested both human and rat FFAR2, and found that the 379 
FFAR2 specific ligand, CFMB, is a full agonist to human as well as rat FFAR2. Hence, the negative results 380 
here seem to exclude an important action of FFAR2 on L-cell secretion in the rat colon. In our lab we have 381 
studied the effects of both the FFAR2 and the FFAR3 selective agonists using the isolated perfused mouse 382 
pancreas, and both showed significant potentiation of somatostatin secretion (Ørgaard et al., unpublished), 383 
demonstrating that the compounds are compatible with our experimental approach. Together, the data 384 
confirm that the ligands applied were administered in an active form and that missing impact on colonic 385 
hormone release was not due to trivial technical problems. Furthermore, in the receptor studies, SCFAs as 386 
well as CFMB activated FFAR2-mediated Gαq activity; however, acetate, propionate and butyrate all 387 
showed low-potent, partial weak agonism towards human as well as rat FFAR2, indicating that the possible 388 
interaction of SCFAs with FFAR2 is not physiologically relevant. Among the SCFAs, propionate was found to 389 
be the most potent ligand on rat FFAR2, but as already mentioned propionate was found to have no effect 390 
on colonic endocrine secretion. Thus, our data suggest that neither FFAR2 nor FFAR3 are necessarily 391 
involved in the enhanced colonic hormone secretion mediated by SCFAs in the rat. Other, less investigated, 392 
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receptor candidates for SCFAs include the rat olfactory receptor Olr59 (mouse ortholog Olfr78, human 393 
ortholog OR51E2) which is shown to induce Gαs-mediated cAMP accumulation upon activation (45). The 394 
receptor is widely expressed in the sensory neurons, while Olfr78/GLP-1 co-expression is found to be very 395 
limited (16%) (24). GPR109A represents yet another possible SCFA target, and seems to be involved in 396 
regulation of inflammation (14). The receptor is activated by high concentrations of butyrate (1 mM), but 397 
not by acetate and propionate (2, 34). Moreover, activation of GPR109A induces Gαi-mediated intracellular 398 
cAMP inhibition (2, 64). Olr59 and GPR109A activation are therefore unlikely to explain the results of the 399 
present study.  400 
   401 
Studies on L-cell secretion have mainly focused on nutrient-induced small intestinal hormone release. 402 
Glucose is the most extensively studied secretagogue and consensus seems to be that uptake initiates 403 
membrane depolarization, and perhaps closure of ATP-sensitive K+ channels, which cause a rise in 404 
intracellular Ca2+, triggering the Ca2+-dependent exocytosis of GLP-1 containing vesicles (3, 38, 53, 60). 405 
Opening of voltage-gated Ca2+-channels seems also to be involved in the SCFA-mediated GLP-1 and PYY 406 
response, as inhibition of these channels by nifedipine administration completely blocked the responses. 407 
The KATP-channel opener diazoxide causes hyperpolarization of the L-cells as opening of these channels 408 
leads to further efflux of K+. When co-infused with the acetate and butyrate cocktail, diazoxide caused 409 
complete attenuation of the colonic hormone response to these SCFAs, and also inhibited the basal 410 
secretion, indicating that the actual membrane potential and the ion currents behind it are essential for the 411 
colonic hormone secretion. Moreover, SCFA-induced GLP-1 and PYY secretion were lost by blockage of ATP 412 
synthesis by 2,4-dinitrophenol indicating that SCFAs may be metabolized by the colonic cells and act via 413 
stimulation of ATP production and possibly actions on the KATP-channels (either in the L-cell or in a putative 414 
stimulating neighbour cell) as suggested above. Interestingly, the secretory response to the Gαq-activator 415 
bombesin (our positive control), which stimulates GLP-1 secretion by phospholipase C activation and 416 
mobilization of intracellular Ca2+, rather than by depolarization, was not affected by the prior 2,4-417 
dinitrophenol infusion, supporting that this additional mechanism for colonic hormone secretion remained 418 
unaffected by the acute ATP-depletion. Taken together, data lead us to suggest that acetate and butyrate 419 
are taken up by the L-cells followed by intracellular metabolism, which impacts the ATP/ADP ratio end 420 
causes L-cell membrane depolarization leading to GLP-1 and PYY secretion by activation of voltage-gated 421 
Ca2+-channels and uptake of extracellular Ca2+. This would be consistent with the inability of propionate to 422 
stimulate secretion since this 3-carbon molecule is poorly metabolized in the peripheral tissues of most 423 
mammals (13, 61). 424 
 425 
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Through secretion of GLP-1 and PYY, SCFAs may indirectly affect host metabolism by increasing satiety and 426 
decreasing gastric emptying and gut motility (25, 47). Additionally, SCFA-mediated GLP-1 secretion may 427 
exert a beneficial effect on glucose metabolism by potentiating glucose-stimulated insulin secretion from 428 
pancreatic beta-cells (46). The most important observations regarding the relationship between SCFAs and 429 
L-cell secretion derive from studies of the ultimate model: the living human being. However, the 430 
mechanistic approach applied in our study is not possible in humans, and therefore we find the perfused 431 
rat colon the best model for our study, though caution obviously is needed when translating findings to 432 
humans. Currently, evidence regarding an influence of SCFAs on hormone secretion in humans is rather 433 
sparse, but SCFAs have been reported to affect PYY, but not GLP-1, secretion when rectally infused into the 434 
human colonic lumen (10, 70). In contrast, colonic SCFA administration to healthy humans has been found 435 
to have no effect on plasma PYY or GLP-1 although H2 in exhaled air (signal of colonic fermentation) 436 
increased (62). This is again contrasted by a study where colonic fermentation, stimulated by one week’s 437 
fructo-oligosaccharide intake, increased plasma GLP-1, but not PYY, in patients with gastroesophageal 438 
reflux disease (54). Short bowel patients with intact colon show increased fasting plasma GLP-1 and PYY 439 
levels (31) as well as increased responses to an oral carbohydrate intake (49), indicating that the endocrine 440 
secretion from the colon may be of physiological importance. A relationship between high fibre intake and 441 
satiety has been found in other human studies (16), but whether this is a direct effect of SCFA production 442 
and GLP-1 secretion is not known. Taken together, SCFAs may be able to impact PYY and/or GLP-1 secretion 443 
in humans, but due to the complex nature of clinical studies and conflicting results, more research is 444 
needed in order clarify the role of SCFAs. Since L-cells are numerous in the colon and the colon is able to 445 
produce active GLP-1 (17, 23, 63), the endocrine colon has the potential to influence our overall metabolic 446 
status. Normally, however, the effects of GLP-1 derived from the colon may largely be local such as delaying 447 
transit time as seen in the small intestine (67). This could also be a result of large amounts of SCFAs 448 
generated from bacterial fermentation. However, looking at the present study, data suggest that in the rat 449 
acetate and butyrate are primarily used as a colonocyte energy source, being metabolized intracellularly to 450 
ATP. This may subsequently lead to L-cell depolarization activating voltage-gated Ca2+-channels and 451 
triggering the Ca2+-dependent exocytosis of peptide containing vesicles, all of it independent of FFAR2 and 452 
FFAR3. Further studies are required to understand endocrine functions and the therapeutic potential of the 453 
colonic endocrine cells.  454 
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 659 
Figure legends 660 
Figure 1: GLP-1 and PYY secretion (fmol/min) from the isolated perfused rat colon in the absence of the 661 
phosphodiesterase inhibitor (IBMX), mean±SEM, n=4 in each group. A) 1 mM vascular acetate infusion 662 
(GLP-1: acetate 1st; p=0.661, acetate 2nd; p=0.643, PYY: acetate 1st; p=0.391, acetate 2nd; p=0.278). B) 100 663 
mM luminal acetate infusion (GLP-1: p=0.898, PYY: p=0.078). C) 1 mM vascular propionate infusion (GLP-1: 664 
propionate 1st; p=0.402, propionate 2nd; p=0.324, PYY:  propionate 1st; p=0.592, propionate 2nd; p=0.674). D) 665 
100 mM luminal propionate infusion (GLP-1: p=0.406, PYY: p=0.260). E) 1 mM vascular butyrate infusion 666 
(GLP-1: butyrate 1st; p=0.443, butyrate 2nd; p=0.072, PYY: butyrate 1st; p=0.092, butyrate 2nd; p=0.237). F) 667 
100 mM luminal butyrate infusion (GLP-1: p=0.249, PYY: p=0.540). A-F) 10 nM bombesin (vascularly) was 668 
included at the end of each experiment as a positive control. 669 
 670 
Figure 2: GLP-1 and PYY secretion from the isolated perfused rat colon in the presence of 10 µM IBMX 671 
(fmol/min and baseline subtracted total output during 5 min (1st: min 12-16, 2nd: min 42-46) vascular (A,C,E) 672 
and 10 min (min 12-21) luminal (B,D,F) infusion), mean±SEM, n=6 in each group. * indicates significant 673 
increase from baseline (*p<0.05). A) 1 mM vascular acetate infusion (GLP-1: acetate 1st; p=0.045, acetate 674 
2nd; p=0.029, PYY: acetate 1st; p=0.029, acetate 2nd; p=0.023). B) 100 mM luminal acetate infusion (GLP-1: 675 
p=0.021, PYY: p=0.951). C) 1 mM vascular propionate infusion (GLP-1: propionate 1st; p=0.968, propionate 676 
2nd; p=0.444, PYY: propionate 1st; p=0.067, propionate 2nd; p=0.611). D) 100 mM luminal propionate 677 
infusion (GLP-1: p=0.468, PYY: p=0.328). E) 1 mM vascular butyrate infusion (GLP-1: butyrate 1st; p=0.049, 678 
butyrate 2nd; p=0.047, PYY: butyrate 1st; p=0.027, butyrate 2nd; p=0.022). F) 100 mM luminal butyrate 679 
infusion (GLP-1: p=0.012, PYY: p=0.002). A-F) 10 nM bombesin (vascularly) was included at the end of each 680 
experiment as a positive control. 681 
 682 
Figure 3: GLP-1 and PYY secretion from the isolated perfused rat colon in the presence of IBMX, 683 
mean±SEM, n=6 in each group. * indicates significant increase from baseline (*p<0.05, **p<0.01, 684 
***p<0.001) and Δ indicates significant difference between response values (Δp<0.05). A) Vascular infusion 685 
of a cocktail of 0.1 mM and 1 mM acetate/butyrate solution (fmol/min) (GLP-1: 0.1 mM cocktail; p=0.003, 1 686 
20 
 
mM cocktail; p=0.0005, PYY: 0.1 mM cocktail; p=0.003, 1 mM cocktail; p=0.005). C) Luminal infusion of 100 687 
mM acetate/butyrate solution (fmol/min) (GLP-1: p=0.048, PYY: p=0.048). B) Baseline subtracted total GLP-688 
1 and PYY output during 5 min (1st: min 12-16, 2nd: min 42-46) vascular infusions. Grey bars arise from figure 689 
2 (GLP-1: from acetate alone 39.6±3.9 to cocktail 67.6±7.3 fmol/min; p=0.023, from butyrate alone 690 
40.2±4.8 to cocktail 67.6±7.3 fmol/min; p=0.057, PYY: from acetate alone 25.0±1.7 to cocktail 28.9±2.9 691 
fmol/min; p=0.413, from butyrate alone 24.4±2.1 to cocktail 28.9±2.9 fmol/min, p=0.408). D) Baseline 692 
subtracted total GLP-1 and PYY output during 10 min (min 12-21) luminal infusions. Grey bars arise from 693 
figure 2 (GLP-1: from acetate alone 22.5±1.0 to cocktail 34.0±2.5 fmol/min; p=0.008, from butyrate alone 694 
33.6±1.9 to cocktail 34.0±2.5 fmol/min, p=0.850, PYY: from acetate alone 9.2±0.7 to cocktail 27.4±2.5 695 
fmol/min; p=0.014, from butyrate alone 14.3±0.5 to cocktail 27.4±2.5 fmol/min, p=0.055). A/C) 10 nM 696 
bombesin was included at the end of each experiment as a positive control. 697 
 698 
Figure 4: Measurements of acetate, propionate and butyrate in the effluent perfusion samples before and 699 
after SCFA administration (100 mM) to the lumen of the isolated perfused rat colon, mean±SEM, n=3-6 in 700 
each group. Ace: acetate, But: butyrate, Pro: propionate.  701 
 702 
Figure 5: GLP-1 and PYY secretion from the isolated perfused rat colon in the presence of IBMX (fmol/min 703 
and baseline subtracted total output during 5 min (A: min 12-16, C: min 16-20, D: 1st; min 12-16, 2nd; min 704 
52-56) vascular infusion), mean±SEM, n=6 in each group. * indicates significant increase from baseline 705 
(*p<0.05, **p<0.01). A) Vascular infusion of 10 µM FFAR2 agonist (CFMB) (GLP-1: p=0.088, PYY: p=0.150). 706 
B) IP3 assay conducted on transient transfected COS-7 cells expressing either human or rat FFAR2. Acetate, 707 
propionate, and butyrate show low-potent partial weak agonism on both human and rat FFAR2 compared 708 
to CFMB, which is a full agonist towards FFAR2 C) Vascular infusion of 10 µM FFAR3 agonist (AR420626) 709 
(GLP-1: p=0.182, PYY: p=0.011). D) Vascular infusion of a 1 mM cocktail solution of acetate and butyrate 710 
followed by vascular administration of the same acetate/butyrate cocktail co-infused with 10 µM FFAR3 711 
antagonist (AR399519) (GLP-1: cocktail 34.8±4.7 to cocktail +FFAR3 antagonist 35.6±3.7 fmol/min, p=0.922, 712 
PYY: cocktail 20.4±2.0 to cocktail +FFAR3 antagonist 25.8±2.1 fmol/min, p=0.142). A/C/D) 10 nM bombesin 713 
was included at the end of each experiment as a positive control. 714 
 715 
Figure 6: GLP-1 and PYY secretion from the isolated perfused rat colon in the presence of IBMX, 716 
mean±SEM, n=6 in each group. * indicates significant increase from baseline (*p<0.05, **p<0.01, 717 
***p<0.001) and Δ indicates significant difference between response values (Δp<0.05, ΔΔp<0.01). A) 718 
Vascular infusion of a 1 mM cocktail solution of acetate and butyrate followed by vascular administration of 719 
21 
 
same acetate/butyrate cocktail co-infused with 10 µM nifedipine (fmol/min) (GLP-1: cocktail 61.3±6.4 to 720 
cocktail +nifedipine 30.6±3.3 fmol/min, p=0.045, PYY: cocktail 40.1±2.5 to cocktail +nifedipine 24.1±1.9 721 
fmol/min, p=0.043). C) Vascular infusion of a 1 mM cocktail solution of acetate and butyrate followed by 722 
vascular administration of same acetate/butyrate cocktail co-infused with 250 µM diazoxide (fmol/min) 723 
(GLP-1: cocktail 84.6±8.7 to cocktail +diazoxide 22.5±3.5 fmol/min, p=0.004, PYY: cocktail 42.7±2.9 to 724 
cocktail +diazoxide 13.6±0.9 fmol/min, p=0.003). E) Vascular infusion of a 1 mM cocktail solution of acetate 725 
and butyrate followed by vascular administration of same acetate/butyrate cocktail co-infused with 10 µM 726 
2,4-dinitrophenol (fmol/min) (GLP-1: cocktail 56.6±6.5 to cocktail +2,4-dinitrophenol 24.2±24 fmol/min, 727 
p=0.007, PYY: cocktail 36.3±4.8 to cocktail +2,4-dinitrophenol 14.5±1.3 fmol/min, p=0.021). B/D/F) Baseline 728 
subtracted total GLP-1 and PYY output during 5 min (1st: min 12-16, 2nd: min 47-51) of infusion. A/C/E) 10 729 
nM bombesin was included at the end of each experiment as a positive control. 730 
 731 
Table 1: EC50 and Emax values for the FFAR2 agonist (CFMB) as well as for acetate, propionate, and butyrate 732 
on both human and rat FFAR2. 733 
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Table 1 
 Human FFAR2 Rat FFAR2 
Log 
(EC50) 
±SEM EC50  
(mM) 
Emax of CFMB 
activity (%) 
Fold change to 
EC50 of CFMB 
n Log 
(EC50) 
±SEM EC50 
(mM) 
Emax of CFMB 
activity (%) 
Fold change to 
EC50 of CFMB 
n 
CFMB -6.09 0.11 0.0008 100 1 4 -6.66 0.07 0.0002 100 1 3 
Acetate -3.32 0.30 0.48 64 589 4 -3.78 0.12 0.17 81 759 3 
Propionate -3.55 0.15 0.28 69 339 4 -3.78 0.10 0.17 93 759 3 
Butyrate -3.30 0.18 0.50 42 617 4 -3.77 0.13 0.17 57 776 3 
